Greenspring Advisors LLC Grows Stake in AbbVie Inc. $ABBV

Posted by Stanley Muller on Jun 4th, 2026

Greenspring Advisors LLC boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 139.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,023 shares of the company’s stock after purchasing an additional 3,512 shares during the period. Greenspring Advisors LLC’s holdings in AbbVie were worth $1,376,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of ABBV. Chelsea Counsel Co. purchased a new position in AbbVie during the third quarter worth $26,000. Westend Capital Management LLC purchased a new position in AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie during the third quarter worth $31,000. Legacy Wealth Managment LLC ID increased its position in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC increased its position in AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after buying an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. William Blair reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $240.00 price target on shares of AbbVie in a research report on Thursday, April 30th. Finally, UBS Group dropped their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

View Our Latest Stock Analysis on ABBV

AbbVie Stock Up 0.9%

ABBV stock opened at $217.24 on Thursday. AbbVie Inc. has a 52-week low of $181.73 and a 52-week high of $244.81. The stock’s fifty day simple moving average is $209.03 and its 200-day simple moving average is $219.35. The stock has a market capitalization of $383.82 billion, a price-to-earnings ratio of 107.02, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter last year, the firm earned $2.46 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. As a group, analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: The UK drug-cost watchdog recommended AbbVie’s ovarian cancer therapy Elahere for patients with a hard-to-treat form of ovarian cancer, boosting the drug’s commercial prospects in a key market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
Positive Sentiment: AbbVie won EU approval for AQUIPTA (atogepant) as an acute treatment for migraine in adults, adding a second approved migraine indication and expanding the drug’s revenue opportunity. AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine
Positive Sentiment: The European Commission also authorized an expanded label for VENCLYXTO, which could broaden use in combination therapies and support oncology sales. AbbVie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO®
Positive Sentiment: AbbVie’s update on a Japan safety study for RINVOQ drew attention to ongoing development and post-market monitoring, though the details appear to be part of routine clinical follow-up rather than a major catalyst. AbbVie’s RINVOQ Safety Study In Japan
Neutral Sentiment: AbbVie also said it will present at the Goldman Sachs healthcare conference next week, which usually keeps investors focused on management commentary but is not a direct business update. AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Company Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.